Conditional Knockout of Proximal Tubule Mitofusin 2 Accelerates Recovery and Improves Survival after Renal Ischemia

Jonathan M. Gall,* Zhiyong Wang,* Ramon G. Bonegio,* Andrea Havasi,* Marc Liesa,† Pradheep Vemula,* and Steven C. Borkan*

*Renal Section and †The Obesity Center, Boston Medical Center, Boston, Massachusetts

ABSTRACT

Proximal tubule (PT) cells are critical targets of acute ischemic injury. Elimination of the mitochondrial fusion protein mitofusin 2 (Mfn2) sensitizes PT cells to apoptosis in vitro. However, the role of PT Mfn2 in ischemic AKI in vivo is unknown. To test its role, we evaluated the effects of conditional KO of PT Mfn2 (cKO-PT-Mfn2) on animal survival after transient bilateral renal ischemia associated with severe AKI. Forty-eight hours after ischemia, 28% of control mice survived compared with 86% of cKO-PT-Mfn2 animals (P,0.001 versus control). Although no significant differences in histologic injury score, apoptosis, or necrosis were detected between genotypes, cKO-PT-Mfn2 kidneys exhibited a 3.5-fold increase in cell proliferation restricted to the intrarenal region with Mfn2 deletion. To identify the signals responsible for increased proliferation, primary PT cells with Mfn2 deficiency were subjected to stress by ATP depletion in vitro. Compared with normal Mfn2 expression, Mfn2 deficiency significantly increased PT cell proliferation and persistently activated extracellular signal–regulated kinase 1/2 (ERK1/2) during recovery from stress. Furthermore, stress and Mfn2 deficiency decreased the interaction between Mfn2 and Ras detected by immunoprecipitation, and purified Mfn2 dose-dependently decreased Ras activity in a cell-free assay. Ischemia in vivo also reduced the Mfn2-RAS interaction and increased both RAS and p-ERK1/2 activity in the renal cortical homogenates of cKO-PT-Mfn2 mice. Our results suggest that, in contrast to its proapoptotic effects in vitro, selective PT Mfn2 deficiency accelerates recovery of renal function and enhances animal survival after ischemic AKI in vivo, partly by increasing Ras-ERK–mediated cell proliferation.


Efforts to modify the untoward consequences of renal ischemia have primarily focused on limiting the initial degree of cell and tissue injury that contribute to AKI. However, because the timing of the ischemic insult is often unknown in human AKI, therapeutic efforts that accelerate epithelial cell proliferation are highly practical for promoting organ recovery. During ischemic organ failure, epithelial cell mitochondria in the proximal tubule (PT) undergo dramatic morphologic changes.1–4 Select proteins induce mitochondria to undergo fission or fusion, resulting in short or elongated mitochondria, respectively. In fact, organelle shape is a life-and-death matter because mitochondrial morphology mediates its susceptibility to outer membrane injury by BCL2 family proteins that cause apoptosis.1,3,4

In the kidney, mitofusins 1 and 2 (Mfn1 and 2), both located on the outer mitochondrial membrane, have emerged as key determinants of mitochondrial fusion and organelle function.4,5 These proteins optimize oxidative metabolism by ensuring dynamic mitochondrial remodeling,5 facilitate mitochondrial...
division during mitosis,6–7 and are required for proper mitochondrial quality control and recycling by mitophagy.8 In neurons and epithelial cells, mitochondrial fission and fusion are critical for maintaining polarity by promoting mitochondrial transport to the appropriate intracellular location.7,9 In addition to their role in controlling organelle shape and size, mitofusins control calcium flux between endoplasmic reticulum and mitochondria.10 Recently, select proteins that regulate mitochondrial morphology have also been shown to exert potent effect on cell proliferation,11–13 a process that is critical for organ repair and recovery after an ischemic insult. After renal ischemia, extracellular regulated kinases (ERK) have been implicated in promoting cell proliferation and repair.14–16

Although in vitro studies, including our own, provide a strong link between mitofusins and PT cell apoptosis,1,4 the hypothesis that mitofusins regulate ischemic AKI has not been directly tested. On one hand, selective deletion of Mfn2 in the PT might aggravate ischemic AKI by increasing renal cell apoptosis.3 However, Mfn2 (previously known as hyperplasia suppressor gene or HSG) could also exert potent “off target” effects on cell proliferation through p21Ras that are independent of mitochondrial dynamics.11,12 If Mfn2 suppressed proliferation, a major contributor to renal recovery after stress,14,16 then reducing Mfn2 in the PT might accelerate organ recovery. To assess the role of cell type–specific Mfn2 in mediating organ dysfunction after ischemia, we conditionally manipulated Mfn2 expression in the PT epithelial cell, a primary target of ischemic stress.1,4,17 We determined that PT Mfn2 deficiency markedly increases animal survival after transient renal ischemia. We suggest that this protection is partly mediated by enhanced proliferation of PT epithelial cells after stress. Using complementary in vivo and in vitro studies, we identified that selective Mfn2 deficiency in the PT promotes proliferation by activating Ras and ERK1/2 signaling pathways. This study identifies a mechanistic approach for increasing the proliferation of surviving PT cells after a severe, potentially lethal ischemic event.

RESULTS

Establishment of a Mouse Model with Inducible Deletion of Mfn2 Expression Specifically in Renal PT Cells

Triple-crossing was used to assess the efficacy of Kap2-Cre–driven PT Mfn2 knockout (KO) and yielded Kap2-Cre+/Mfn2ff/tomato and Kap2-Cre/Mfn2ff/tomato littermates (genotyping data not shown) under the control of a testosterone-inducible, PT-specific KAP2 promoter.18 In male Kap2-Cre+/Mfn2ff/tomato mice, endogenous testosterone failed to activate Kap2-Cre in the PT or cause conditional KO of Mfn2 (data not shown). Within 2 weeks of exogenous testosterone administration, mean serum testosterone levels increased by >14.5-fold in both male and female mice (53 ± 62–772 ± 240 ng/dl). In Kap2-Cre+/Mfn2ff/tomato mice, testosterone treatment resulted in selective elimination of PT tomato red expression; green fluorescent protein (GFP) appeared and Mfn2 was selectively eliminated (Figure 1A, right versus left panel). In contrast, both glomeruli and blood vessels continued to appear red in testosterone-treated mice. Immunoblot showed that testosterone treatment reduced Mfn2 content by about 50% (P<0.05) as compared with renal cortical homogenates from animals lacking Kap2Cre (Figure 1B). The reduction in Mfn2 content in these tissue extracts reflects the fact that the PT epithelial cell represents only one of the cell types present in renal cortex and that Kap2Cre expression is incomplete. Because Mfn2 is critical for maintaining mitochondrial fusion in murine kidney cells,1,4 site-specific Mfn2 KO should change organelle shape from elongated to short or “punctate” in Kap2Cre positive PT epithelial cells. In fact, mitochondria did undergo a marked shape change in Kap2Cre-expressing PT cells. Specifically, Kap2Cre-positive tubules that express Cre (i.e., GFP-positive tubules) exhibited punctate (Figure 1C, upper inset) versus elongated mitochondria (lower panel) in adjacent PTs that contained red fluorescent protein and failed to express Kap2Cre.

Effect of Conditional Knockout-PT Mfn2 on Animal Survival, Renal Function, and Histologic Injury

Once the positive effect of exogenous testosterone on Kap2Cre expression was determined in the tomato red mouse, Kap2-Cre and Mfn2ff mice were crossed and littermates were used for all additional experiments. Twenty-four and forty-eight hours after 28 minutes of bilateral renal pedicle clamping, renal function was assessed in surviving Kap2-Cre/Mfn2ff mice with conditional KO of PT (cKO-PT) Mfn2. The mean serum BUN level (a reliable estimate of renal function in this ischemia model that parallels measures of serum creatinine in this model19-21) was significantly lower in mice with cKO-PT Mfn2 (P<0.04) at both time points (Figure 2A). Importantly, BUN was measured in only 9 of 18 of the surviving control animals, likely underestimating the severity of AKI in this group. In fact, <30% of the surviving control and >85% of cKO-PT Mfn2 mice survived more than 48 hours after renal ischemia (Figure 2B). To quantify the severity of ischemic injury, randomly selected tissue sections were blindly examined 24 hours after ischemia. After ischemia, tissues sections harvested from both control and cKO-PT Mfn2 exhibited marked changes in the degree of tubular injury, vascular congestion, and inflammation (Table 1). However, no statistically significant difference in the severity of necrosis or apoptosis between groups was noted in postischemic tissue at the time point of maximal renal dysfunction, suggesting that tubular recovery, potentially mediated by PT cell regeneration, was more robust in cKO-PT Mfn2 mice.

Effect of cKO-PT Mfn2 on Postischemic Proximal Tubule Proliferation

Compared with control, bromodeoxyuridine (BrdU) incorporation, a marker of cell proliferation, was dramatically increased in the renal cortices of cKO-PT Mfn2 mice (Figure 3A). At higher magnification, selective BrdU incorporation in the PT, the structure lacking Mfn2, was clearly evident (Figure 3A, lower panels). Only about 15% of control PTs incorporated BrdU after
ischemia. In contrast, >50% of PTs stained with BrdU in postischemic Mfn2 KO kidneys (P<0.05) (Figure 3B). The amount of BrdU staining in the pre- or postischemic renal medulla did not significantly differ between these two groups (0.1 versus 0.15 cells/high-power field in control and cKO-PT Mfn2, respectively). Commensurate with similar baseline rates of cell proliferation, no difference in renal size was observed between control and cKO-PT mice (data not shown). In primary PT cells harvested from Mfn2KO mice, exposure to adenovirus containing Cre resulted in an 80%–90% reduction in steady-state Mfn2 content in vitro (Figure 4, A and B). Twenty-four hours after ATP depletion, Mfn2 KO (Cre plus) cells exhibited significantly higher proliferation rates, as evidenced by greater BrdU incorporation compared with control exposed to empty AdV (Cre minus; P<0.05). The addition of an ERK1/2 inhibitor (U0126, 20 μM) completely prevented the increase in proliferation associated with Mfn2 deficiency (Figure 5). In the absence of ischemic stress, cell proliferation did not differ between Mfn2-replete and -deplete proximal tubule cells (data not shown).

Mfn2 Knockout Regulates Proximal Tubule Cell Proliferation via an ERK1/2-Dependent Pathway

Compared with baseline, ATP depletion activates extracellular regulated kinase (phospho-ERK1/2) in both control and Mfn2 KO primary cells (Figure 6, A and B). In both groups, ERK1/2 was markedly activated above steady-state Mfn2 protein content in homogenized renal cortices harvested from tomato red mice either with (Cre+) or without (Cre−) Cre expression in the presence of testosterone (T; left panel); densitometric analysis of three separate experiments (right panel). *P<0.05; n=3. RDU, relative density units; error bars represent mean±SEM. (C) Mitochondrial morphology after testosterone exposure in adjacent cortical PTs of a Kap2-Cre+/Mfn2f/f/tomato mouse after induction of Cre expression with testosterone; Mfn2-replete tubule with persistent tomato red expression and elongated mitochondria (upper inset); punctate mitochondria within a GFP fluorescent tubule (blue; lower inset); mitochondria are stained for F1F0 ATPase, an intrinsic outer mitochondrial membrane protein (green) at ×400 magnification.
baseline within 1-hour recovery from stress. However, kinase activation was significantly greater in Mfn2 KO cells at 6, 12, and 24 hours after injury \( (P<0.05 \text{ at each time point}) \). In contrast to the marked changes in p-ERK1/2 associated with ATP depletion and recovery, total ERK1/2 content remained constant at all time points (Figure 6, lower panels). The presence of U0126 (20 \( \mu \text{M} \)) similarly decreased the basal rate of proliferation both in wild-type and Mfn2-deficient renal cells and completely prevented the increase in proliferation associated with ATP depletion in both groups (Figure 6, C and D). Although ERK1/2 activity was almost identical before ischemic stress \( (i.e., \text{at baseline}) \), kinase activation was 80% greater than control in renal cortical homogenates harvested from cKO-PT Mfn2 mice after ischemia \text{in vivo} \ (Figure 6, E and F).

Interestingly, marked interaction between Mfn2 and Ras, an upstream ERK activator, was detected in immunoprecipitates harvested at baseline from nonstressed, Mfn2-replete primary PT cells (Figure 7A, left lane, upper panel). In contrast, decreased Mfn2-Ras interaction was detected during recovery from ATP depletion and in nonstressed renal cells with Mfn2 deficiency \( (Figure 7, A \text{ and } B, \text{middle and right lanes, respectively, in upper pane}l) \). In Mfn2 KO cells, decreased Mfn2-Ras interaction is clearly caused by a marked decrement in Ras from each sample. Similar to the effects of ATP depletion \text{in vitro}, Mfn2-RAS interaction also significantly decreased by about 35% in the renal cortices of mice subjected to ischemia \text{in vivo} \ (Figure 7, C and D). Similar molecular mass of Ras \( (22 \text{ kD}) \) and immunoglobulin light chain \( (30 \text{ kD}) \) precluded reciprocal immunoprecipitation studies. Commensurate with decrement in Mfn2 and Ras interaction during stress, renal cortical Ras activity significantly increased by 50% after ischemia \text{in vivo} \ (Figure 8, A and B). Finally, picomolar amounts of purified human MFN2 markedly decreased Ras activity in a dose-dependent manner by as much as 80% in a cell-free assay \( (Figure 8, C \text{ and } D) \). In contrast, identical concentrations of BSA did not alter Ras activity.

**DISCUSSION**

Although direct evidence is sparse, the PT has been presumed to be a critical mediator of acute ischemic organ failure for decades.22–24 In this study, we altered the expression of a single protein in the PT epithelial cell to assess \( (1) \) its role in mediating ischemic organ failure \text{in vivo} \ and \( (2) \) the potential effects of Mfn2 on PT epithelial cell death and organ recovery after ischemic stress. Because Mfn2 KO exerts potent untoward effects on renal cell survival after \text{in vitro} stress caused by exposure to metabolic inhibitors,1,4 we initially predicted that conditional KO of PT Mfn2 \( (\text{cKO-PT Mfn2}) \) would enhance tubular injury, exacerbate organ failure, and decrease animal survival. Unexpectedly, \text{cKO-PT Mfn2} \ dramatically increased animal survival after a standardized ischemic insult that caused severe AKI and death. In fact, \text{cKO-PT Mfn2} also decreased the severity of renal failure. The modest 15%–20% higher BUN in control probably underestimates a larger decrease in GFR on days 1 and 2 after ischemia because 50% of control mice \( (9 \text{ of } 18) \) died within 24 hours and \( >70\% \) \( (13 \text{ of } 18) \) died within 48 hours after stress, precluding inclusion of their BUN measurements. Although the severity of tubular injury \( (\text{simplification or congestion}) \), obstruction, and tissue inflammation did not significantly differ in \text{cKO-PT Mfn2} \text{mice} \ (Table 1), the degree of histologic evaluation poorly reflects organ function after ischemia.25 Similarly, no differences in the degree of cell apoptosis or necrosis were detected 24 hours after ischemia in control versus \text{cKO-PT Mfn2} \text{mice}, the period of maximal organ dysfunction.19–21

**Figure 2.** Conditional KO of PT Mfn2 (cKO-PT Mfn2) improves postischemic renal function and animal survival. (A) Serial BUN levels 24 and 48 hours after ischemia in control versus cKO-PT Mfn2 littermate mice. The significant difference in BUN observed between Kap2-MFN2 cKO and control animals was compared using repeated-measures ANOVA with the last BUN observation carried forward for nonsurviving animals. \( *P<0.05; \) \( n=18 \text{ or } 22; \) error bars represent mean±SEM. (B) Animal survival at each time point after ischemia. \( *P<0.05; \) \( n \) indicates number of surviving mice.

**Table 1.** Histologic score after renal ischemia

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control</th>
<th>Mfn2 PT-cKO</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simplification</td>
<td>2.2±0.38</td>
<td>2.8±0.25</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Obstruction</td>
<td>2.0±0.45</td>
<td>2.5±0.5</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Congestion</td>
<td>1.6±0.68</td>
<td>2±0.58</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Necrosis</td>
<td>0.4±0.25</td>
<td>1±0.58</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Apoptosis</td>
<td>2.0±0.44</td>
<td>2.3±0.48</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Inflammation</td>
<td>2.0±0.63</td>
<td>2.5±0.5</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Total Injury Score</td>
<td>10.2±2.7</td>
<td>13±2.6</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

Unless otherwise noted, values are expressed as the mean±SD.

**Figure 6.** Total injury score of renal cortical homogenates harvested from cKO-PT Mfn2 littermate mice. The significant difference in BUN observed between Kap2-MFN2 cKO and control animals was compared using repeated-measures ANOVA with the last BUN observation carried forward for nonsurviving animals. The presence of U0126 (20 \( \mu \text{M} \)) similarly decreased the basal rate of proliferation both in wild-type and Mfn2-deficient renal cells and completely prevented the increase in proliferation associated with ATP depletion in both groups (Figure 6, C and D). Although ERK1/2 activity was almost identical before ischemic stress \( (i.e., \text{at baseline}) \), kinase activation was 80% greater than control in renal cortical homogenates harvested from cKO-PT Mfn2 mice after ischemia \text{in vivo} \ (Figure 6, E and F).
The absence of marked changes in the degree of cell death associated with PT Mfn2 deficiency is unexpected. In renal and nonrenal cell types, filamentous mitochondria are relatively resistant to apoptosis compared with fragmented ones.\(^1\),\(^2\),\(^4\),\(^26\) This sensitivity to apoptosis is partly due to their increased susceptibility to Bax-mediated mitochondrial injury.\(^1\),\(^4\) Renal cell apoptosis, especially involving the epithelial cells of the PT, exacerbates ischemic AKI,\(^4\),\(^19\)–\(^21\) strongly suggesting that mitofusin deletion (and the accompanying mitochondrial shortening) would promote organ failure. This hypothesis is consistent with the observation that pharmacologic treatment of mice with an inhibitor of the mitochondrial fission protein Drp-1, improved organ function after renal ischemia in mice.\(^2\) Similar to the present observations, however, major discrepancies between the untoward \textit{in vivo} and favorable \textit{in vitro} consequences of Mfn2 deficiency have been reported. In isolated cardiac myocytes, Mfn2 deficiency increased apoptotic cell death but enhanced myocardial performance after ischemia \textit{in vivo}.\(^26\) This discrepancy could be due to the fact that apoptosis minimizes inflammation or that rapid clearance of severely damaged cells facilitates subsequent repair. Alternatively, the beneficial effect of Mfn2 deficiency after ischemic stress could overshadow its potential for promoting apoptosis.

Ischemic renal injury results in the loss of epithelial cells and cell growth arrest in surviving ones. Subsequent activation, proliferation, and redifferentiation of surviving cells repopulate the tubule, a critical hallmark of renal recovery after ischemia.\(^16\),\(^27\),\(^28\) Compared with control, BrdU incorporation increased 3-fold in the renal cortex of Mfn2 conditional KO mice (Figure 3A). Furthermore, Mfn2 deficiency increased proliferation exclusively in the PT, the only structure targeted for Mfn2 knockout (Figure 1, A and C). In contrast, cell proliferation in the renal medulla did not differ between groups before or after renal ischemia.

Although the source of proliferating cells after a renal insult is debated, recent evidence suggests that surviving, resident PT epithelial cells are more important for replacing epithelial cells lost during injury and organ recovery than stem cells derived from the bone marrow or the kidney itself.\(^29\)–\(^33\) Once attached to the tubular basement membrane, immature cells redifferentiate, regain mature surface markers such as vimentin, and then contribute to vectoral solute transport, a hallmark of normal epithelial cell and organ function.\(^32\),\(^34\) In our study, primary proximal tubule cells with Mfn2 KO exhibited significantly higher rates of proliferation (BrdU incorporation) only 24 hours after metabolic stress \textit{in vitro} (Figure 4C), a time point that matches our \textit{in vivo} observations (Figure 3, A and B). Although the \textit{in vitro} proliferative response was less robust than that detected \textit{in vivo}, longer periods of cell growth (e.g., up to 9 days) enhance the effect of Mfn2 deficiency on cell proliferation.\(^11\),\(^12\)

Recent investigations provide mechanistic clues for Mfn2-mediated PT cell proliferation. Previously referred to as hyperplasia suppressor gene, Mfn2 has multiple mechanism for regulating cell proliferation, including a Ras-like motif\(^35\); an amino terminal domain that binds active Ras\(^12\); and a carboxy terminal domain that binds RAF-1, a kinase downstream of Ras.\(^12\) In fact, Mfn2 has...
been linked to Ras-mediated proliferation in glomerular mesangial cells. In the present study, substantial evidence implicates RAS signaling as central to the effect of Mfn2 deficiency on renal epithelial cell growth. First, ATP depletion (Figure 6, C and D) activates RAS. Second, Mfn2 deficiency increases RAS activity after ischemia in vivo (Figure 8, A and B). Third, ischemic stress decreases the interaction between Mfn2 and active RAS in a manner predicted to increase free RAS (Figure 7, A–D). Finally, purified Mfn2 decreases RAS activity in a dose-dependent manner in a cell-free assay (Figure 8, C and D).

We suggest the decrement in Mfn2-Ras interaction caused by selective MFN2 deficiency increases free Ras and ERK1/2 activation, resulting in postischemic PT cell proliferation with improved animal survival. Because no difference in the rate of cell proliferation was detected in the absence of ischemic stress, we hypothesize that the antiproliferative effect of Mfn2 is evident only in the presence of signals that activate Ras/ERK. The observation that Ras and ERK are activated by renal ischemia in response to multiple growth factors, including hepatocyte growth factor, EGFR, PDGF, TGF-β, and IGF, support this contention. Importantly, an established ERK inhibitor completely prevented the increase in ERK activation (Figure 6, C and D) and cell proliferation (Figure 5) caused by Mfn2 deficiency. These observations indicate that ERK is a relevant proliferative signal in our ischemia model. Interestingly, Mfn2-deficient proximal tubule cells exhibited persistent ERK1/2 activation 6–24 hours after ischemic stress (Figure 6, A and B, E and F), the same time frame in which marked epithelial cell proliferation was detected both in vitro (Figure 5) and in vivo (Figure 3, A and B).

In fact, the stimulatory effect of Mfn2 deficiency on PT cell proliferation may be even greater because other investigators have shown proliferation peaks between 48 and 72 hours after renal ischemia. ERK activation is required for cell proliferation. In the kidney, the preponderance of evidence suggests that ERK 1/2 activation protects against oxidant, hypoxic, and ATP depletion–mediated injury of renal epithelial cells in vitro as well as oxidant and ischemia-reperfusion injury in vivo. Although GFR was not measured, biochemical ERK inhibition promoted the retention of focal adhesions and preserved the actin cytoskeletal network in a single study of renal ischemia. In contrast to ischemia/reperfusion models, ERK inhibition (versus activation) protects against cis-platinum–induced AKI, partly by its effect on apoptosis inhibition and partly by modulating renal epithelial cell cilia. However, few studies (including the present report) have used molecular techniques to selectively manipulate individual ERKs. Presumably, sequestration/inactivation of Ras (and perhaps Raf) by Mfn2 limits PT cell division after stress by interfering with ERK1/2. On the basis of our current observations, we suggest that disrupting Mfn2-Ras interaction is a promising mechanism for promoting renal epithelial cell growth and organ function, as well as for enhancing survival after severe ischemia. Despite the...
potential for Mfn2 depletion to aggravate apoptosis in vitro,1,4,26 we suggest that Mfn2 deficiency dramatically protects against renal ischemia in vivo, partly by accelerating PT cell proliferation.

CONCISE METHODS

Chemicals

All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise indicated.

Animals

Because embryonic Mfn2 KO is lethal, mitofusin 2 floxed animals (Mfn2fllox) were generated by Dr. Chan’s laboratory.47 Conditional PT Mfn2 KO was created by breeding Mfn2fllox animals with animals expressing Cre recombinase under the control of the Kap2 promoter (Kap2-Cre, B6. Cg-Tg[Kap-cre]29066/2Sig/J18), resulting in Kap2-Cre+/Mfn2f/f mice. After additional crossing with the tomato red mouse, Kap2-Cre+/Mfn2f/f/tomato and Kap2-Cre-/Mfn2f/f/tomato littermates were studied. The Kap2 promoter requires the addition of testosterone to active and express Cre (Dr. Curt Sigmund, University of Iowa, personal communication). Silastic tubes (I.D. = 1.5 mm; Dow Corning, Midland, MI) were filled with 1 mg testosterone propionate (MP Biomedicals, Solon, OH) and sealed with cyanoacrylate glue before subdermal implantation in the right flank of both Kap2-Cre+/Mfn2f/f/tomato and Kap2-Cre-/Mfn2f/f/tomato littermates for 2 weeks. The effect of this maneuver on serum testosterone levels was assessed using liquid chromatography/mass spectometry to measure total testosterone (Hormone Assay Laboratory, Boston University School of Medicine, Boston, MA). In all subsequent renal ischemia studies, histology, renal function, and biochemical measures were assessed in Kap2Cre plus/MFN2ff mice crossed with Kap2Cre minus/MFN2ff animals. The resulting MFN2 ff mice were each treated with exogenous testosterone. To minimize the potential effects of background genetic differences, littermates were subjected to genotyping and then divided into two experimental groups: Kap2 Cre positive or Kap2 Cre negative.

Figure 6. Mfn2 deficiency-mediated enhances ERK1/2 activity after ATP depletion or renal ischemia. (A) Immunoblot analysis of phospho- and total ERK1/2 content in lysates at baseline (Base), immediately after (0 Recovery) and at 1- to 48-hour recovery. (B) Densitometric analysis of phospho- and total ERK1/2 content (ERK activity) in lysates harvested from control (wild type [WT]; black bars) versus Mfn2 KO (KO; white bars) cells before (base) and at 0- to 48-hour recovery after ATP depletion; error bars represent mean±SEM. n=3 separate studies. *P<0.05; n=3–4. (C) Immunoblot analysis of phospho- and total ERK1/2 content before and after ATP depletion in the presence versus absence of 20 μM U0126. (D) Densitometric analysis of three separate studies performed as described in part C; no significant differences between WT and KO were detected at any time point; error bars represent mean±SEM. (E) Immunoblot of phospho- and total ERK1/2 content in homogenates of renal cortex harvested from control or Mfn2 KO mice before and after renal ischemia. (F) Densitometric analysis of three separate studies performed as described in part E; error bars represent mean±SEM. *P<0.05 versus wild type.
Renal Ischemia

In Vivo

Six-week-old mice weighing 22–26 g were used to perform ischemia/reperfusion studies under standardized conditions as described elsewhere. After intramuscular injection of buprenorphine (0.075 mg/kg body wt) and intraperitoneal injection of tribromoethanol (250 mg/kg body wt), both kidneys were exposed by a midline incision. Sham-operated mice received identical surgical procedures with the exception that clamps were not applied. For PT-specific Mfn2 KO studies, bilateral renal pedicle occlusion was performed for 28 minutes to assess renal function, survival, histology, BrdU incorporation, apoptosis, and necrosis. After clamp removal, restoration of blood flow was visually confirmed for 1 minute. Renal histology was examined in stained, 5-μm tissue sections (described below). Tubular injury score was assessed in kidney tissue sections fixed with 10% formaldehyde, embedded in paraffin, and cut into 8-μm sections before staining with hematoxylin-eosin reagent. Total injury scores were calculated by a single blinded observer from three randomly selected tissue sections using a 0–3 semi-quantitative score (0=normal structure and 3=severe injury) of brush border simplification, intratubular obstruction, vascular congestion, inflammation, and both apoptosis and necrosis as previously reported.

Primary PT Cell Culture

Three-week-old male mice were euthanized by overdose with inhaled CO2 using established protocols. Immediately after euthanasia, the kidneys were removed and maintained on ice. The cortex was collected, minced, and the digested for six hours with collagenase for 60 minutes at 37°C. The collagenase was neutralized by calf serum and the digested cortex was washed twice with buffer F12 medium. Mouse cells were maintained in a 50/50 (vol/vol) mixture of DMEM-Ham F12 medium containing insulin (5 mg/L), hydrocortisone (50 nM), and apotransferrin (500 μg/L) and were stored at 37°C for 5–7 days in a 5% CO2 incubator.

Metabolic Stress

ATP depletion, an established model of renal ischemia, was induced by exposing cells to glucose-free DMEM that contained adenosine, 1 mM; allopurinol, 0.2 mM; and rotenone, 10 mM (a complex I inhibitor), at 37°C in the presence of 5% CO2 as previously reported. Cells were rinsed three times with glucose-free DMEM followed by DMEM containing the preceding metabolic inhibitors for 60–90 minutes at 37°C with 5% CO2. Cell recovery was initiated by replacing the medium with DMEM containing adenosine, 1 mM; allopurinol, 0.2 mM; and heptanoic acid, 1 mM (a substrate that bypasses complex I inhibition).
These maneuvers result in a 90% reduction in cell ATP content during the period of metabolic stress with prompt recovery of ATP content during recovery.52

In Vitro Mfn2 KO

An adenovirus expressing Cre recombinase was used to transduce Mfn2fl/fl primary PT cells. The cells were infected with adenovirus (multiplicity of infection, 10) overnight and the medium was replaced with complete primary culture media for 48 hours before the experiments. Recombination of the loxP sites by Cre recombinase deleted the floxed Mfn2 gene, creating Mfn2-deficient cells in culture. Adenovirus without Cre was used as control.

Antibodies and Immunoprecipitation

Mfn2 (XX-1) and Pan-Ras antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). p-ERK1/2, total ERK1/2, and β-actin antibodies were purchased from Cell Signaling Technology (Danvers, MA). The appropriate secondary antibody conjugated to AlexFluor-488 (Invitrogen) was used for immunofluorescence, and horseradish peroxidase (Bio-Rad) was used for immunoblot analysis.

Immunoprecipitation was performed as recently described by our laboratory.51 In brief, 7.5×10^6 cells were harvested in buffer containing NaCl, 150 mM; Tris HCl, 10 mM; EDTA, 5 mM; EGTA, 1 mM; 1% Triton X-100; and 0.5% NP-40, with protease inhibitors at a pH of 7.4. Lysates were centrifuged at 10,000 g for 10 minutes at 4°C. Samples containing 400 µg total protein were incubated overnight at 4°C with 2 µg of antibody bound to protein A/G beads. The immune complex was then precipitated and an immunoblot analysis performed to verify the identity of the antigen. Equal amounts of supernatant served as an input control.

Immunoblot Analysis

Cells were lysed in NP-40 lysis buffer containing 150 mM sodium chloride; 50 mM Tris at a pH of 7.5; 1 mM EDTA; 1% nonidet-P-40; and protease inhibitors aprotinin (10 µg/ml), leupeptin (2.5 µg/ml), and 1 mM phenylmethylsulfonyl fluoride. Aliquots of lysates containing 20–30 µg/lane of protein were separated on 8%–12% Tris-glycine polyacrylamide gels. Antigens were detected with enhanced chemiluminescence reagents (Amersham, Piscataway, NJ) using specific antibodies.

Tissue Staining

For immunofluorescent staining of tissue, sections were washed three times for 5 minutes each in PBS, followed by 5 minutes in PBS containing 0.1% SDS. After three additional washes, tissue sections were blocked for 1 hour in PBS containing 5% normal goat serum and 0.3% Triton X-100. Following three washes, sections were incubated for 90 minutes with antibodies against F1F0 ATPase (2 µg/ml) in PBS with 1% BSA and 0.3% Triton X-100. After three PBS washes, sections were incubated in AlexaFluor 488 (1:250 dilution) and AlexaFluor 594 (1:500 dilution) conjugated secondary antibodies (1% BSA, 0.3% Triton X-100 in PBS) for 1 hour, washed three final times in PBS, mounted with Gelvatol with or without Hoechst, and examined by confocal microscopy (PerkinElmer Ultraview Scanning Disk Microscope, Wellesley, MA). Slides were also imaged by phase contrast and wide-field epifluorescence microscopy followed by deconvolution using ImageJ software.

For immunohistochemical tissue staining, sections were deparaffinized, heated in 10 mM sodium citrate (pH, 5.5) for 1 hour in a pressure cooker, and stained with anti-BrdU (1:160 dilution) following the ABC elite kit directions (Vector Laboratories, Burlingame, CA). Sections were developed with ImmPact DAB (Vector Laboratories).

Cell Proliferation Assay In Vivo and In Vitro

BrdU, a synthetic thymidine analogue, can be incorporated into newly synthesized DNA, providing a test of DNA replication, as an indirect measure of cell proliferation. The assay was performed in vivo by giving the mice a single intraperitoneal injection of 1 mg BrdU in 200 µl of sterile PBS before ischemia. BrdU was detected in kidney sections as described earlier. The assay was performed in vitro as described in the product manual from EMD Millipore (Billerica, MA). BrdU synthesis was measured by the incorporation of BrdU into newly synthesized DNA, providing a test of DNA replication, as an indirect measure of cell proliferation. The assay was performed in vivo by giving the mice a single intraperitoneal injection of 1 mg BrdU in 200 µl of sterile PBS before ischemia.
incorporation was detected by addition of peroxidase substrate. Spectrophotometric detection was performed at a wavelength of 450 nm.

**Ras Activity Assay**

A Ras Activation Assay kit (Cell BioLabs, Inc., San Diego, CA) was used to measure enzyme activity. Mfn2 KO PT cells were stressed with 70 minutes of ATP depletion, followed by 1-hour recovery or renal cortical homogenates after 28-min ischemia with 6-hour recovery. The protein was extracted using the manufacturer’s lysis buffer and divided into five aliquots (600 µg each). Purified recombinant human MFN2 protein (OriGene, Rockville, MD) or human serum albumin (Sigma-Aldrich) was added to the protein lysis and incubated on ice for 90 minutes. Ras activity was measured using the Ras-binding domain of Raf-1 to pull down active Ras according to the manufacturer’s protocol. Following separation by SDS PAGE, proteins were transferred to membranes that were probed with an anti–pan-Ras antibody.

**BUN Assay**

Mouse whole blood was collected via the tail vein before and after ischemia and from the heart at the time of euthanasia. Samples were spun in a microcentrifuge at 4000 rpm for 30 minutes and serum was collected. BUN was measured using a QuantiChrom BUN assay kit (Bioassay Systems, Hayward, CA) following the manufacturer’s protocol. Estimates of GFR using serum BUN or Cr are almost identical to those predicted by the Cockcroft–Gault formula.

**Statistical Analyses**

Data were analyzed using Excel (Microsoft, Redmond, WA). Significant differences between groups were determined by ANOVA using repeated measures adjusted by Scheffe test, with p values <0.05 considered to represent statistically significant differences.

**ACKNOWLEDGMENTS**

National Institutes of Health (NIH) grant DK-53387 (S.C.B.), NIH-DK-090558 (R.G.B.), and NIH-DK090143 (A.H.) each supported this research. M.L. is an Evans Research Fellow supported by the Evans Medical Foundation, Boston University Medical Center.

**DISCLOSURES**

None.

**REFERENCES**